News Releases

The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to infuse with no treatment-adverse events or toxicities observed REDWOOD CITY, Calif. , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on

REDWOOD CITY, Calif. , Sept. 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will be participating in the following conferences in September.

JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi anemia and Sickle Cell Disease On track to initiate a new study of JSP191 as a

First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia On schedule to initiate a registrational study in AML in the first quarter of 2023 On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lower-risk, transplant

REDWOOD CITY, Calif. , June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners 2 nd Annual Genetic Medicines Symposium on June

REDWOOD CITY, Calif. , June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42 nd Annual Growth Stock Conference , to be held in

REDWOOD CITY, Calif. , June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022 , at 10:00 a.m.

REDWOOD CITY, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of the first patient in the Company’s sponsored research of the Center for Definitive and Curative

Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023 Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients with MDS or AML presented at the 2022 Transplantation & Cellular Therapy (TCT) Annual Meeting

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients REDWOOD CITY, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. , (NASDAQ: JSPR) a biotechnology company focused on hematopoietic